MTP Connect Appoints New Chief Executive Officer
11th May 18
The body supporting innovation in the medicines and medical devices sector, MTP Connect, has appointed Dr Dan Grant as Chief Executive Officer. He brings extensive experience across the pharmaceutical, medical research and higher education sectors
Key Issues For The Dental Industry —
Formed in 2015, MTPConnect is a not-for-profit organisation which aims to accelerate the rate of growth of the medical technologies, biotechnologies and pharmaceuticals sector to achieve greater commercialisation and establish Australia as an Asia-Pacific hub for MTP companies.
Following an extensive search, it has appointed Dr Dan Grant as Chief Executive Officer. Dr Grant will commence the role in July 2018, bringing a wealth of experience to MTPConnect and the Australian MTP sector, from an extensive career in the pharmaceutical, medical research and higher education sectors.
Dr Grant joins MTPConnect from his position as Pro Vice-Chancellor for Industry Engagement at La Trobe University in Melbourne, where he leads the University’s innovation, commercialisation and industry engagement activities. Dr Grant also oversees the University’s R&D Precinct and was responsible for establishing La Trobe’s business accelerator program and Strategic Innovation Fund.
Prior to joining La Trobe, Dr Grant was the Senior Director and Head of Pfizer’s External Research and Development Innovation group for Australia, New Zealand and Singapore. He has also held roles as Senior Business Development Manager at Melbourne Ventures, a member of the Investment Committee for Uniseed, and as a Senior Business Development Manager for Biocomm Services.
MTPConnect was formed as a not-for-profit organisation in November 2015 as part of the Australian Government’s Industry Growth Centres Initiative. MTPConnect sits at the nexus of the sector, driving collaboration, acting as an independent voice for change, working to establish Australia as an Asia-Pacific hub for MTP companies, and funding big, bold ideas to accelerate growth and drive greater commercialisation opportunities. For information on MTP Connect visit the organisation's website at:
Dr Bronwyn Evans, the chair of MTPConnect, said the appointment of Dr Grant brings new opportunities for growth and advancement, not just within MTPConnect, but for the entire MTP sector in Australia.As announced in February 2018, Sue MacLeman, the first CEO of MTPConnect, will assume the Chair position in place of Dr Bronwyn Evans who is stepping down. With a strong background in University research and industry, Dr Grant will work with the MTPConnect Board and Chair to further develop the organisation by building relationships with industry, government and other stakeholders, both nationally and internationally.
To ensure appropriate governance, there will be a gap between Ms MacLeman stepping down as CEO and taking up the role as Chair. During this three-month period, Dr Evans will remain the Chair and work with the new CEO, with Ms MacLeman to be appointed as a Non-Executive director to assist in transition. In October 2018, following three months as a Non-Executive board member, Ms MacLeman will move to the Chair role and Dr Evans will step down from the Chair and Board role with MTPConnect.
Member Engagement —
ADIA provides leadership, strategy, advocacy and support. Our members set our agenda, fund our activities and directly benefit from the results. With respect to the Association's work to support innovation across the dental industry the team in the ADIA national office receieve advice and guidance from members serviong on the ADIA-MIG Manufacturers Interest Group.
Further Information —
To keep up to date with how ADIA is working to ensure that the Australian Government budget supports the dental industry, subscribe to the Twitter feed @AusDental or follow us on Facebook at www.facebook.com/dental.industry. Alternatively, you can contact the Association via email at email@example.com or by telephone on 1300 943 094.
Currency Of Information & Disclaimer —
This update was issued on 11 May 2018 and please note that changes in circumstances after the publication of material or information may impact upon its accuracy and also change regulatory compliance obligations. The statements, regulatory and technical information contained herein are believed to be accurate and are provided for information purposes only. Readers are responsible for assessing its relevance and verifying the accuracy of the content. To the fullest extent permitted by law, ADIA will not be liable for any loss, damage, cost or expense incurred in relation to or arising as a result of relying on the information presented here.
This publication is available for your use under a Creative Commons Attribution 3.0 Australia licence, with the exception of the ADIA logo, images and where stated.
5th Jan 18
Ensuring that decisions taken by dental professionals on patient diagnostic and treatment options are independent of undue influence by product suppliers is what underpins the industry's new code of practice.
11th Jun 18
Australia's dental industry has provided advice to the Australian Government on the proposed new centralised complaints body for the advertising of medicines and medical devices to the public.